BACKGROUND HIV infected patients receiving antiretroviral therapy (ART) have extensive musculoskeletal system involvement. Arthralgia and myalgia are the most common forms. Fibromyalgia Syndrome (FMS) is a chronic pain syndrome of the musculoskeletal system characterized by diffuse pain including arthralgia and myalgia. These overlapping symptoms are suggested the relationship between HIV and FMS. The primary purpose of this study was to determine the prevalence of FMS in HIV/AIDS patients. The secondary objective was to investigate the effects of FMS on functional status, depression, fatigue, sleep pattern and quality of life. METHODS A total of 225 HIV infected patients who were receiving ART were included in this cross-sectional prospective study. The demographic data of the participants, CD4 T-lymphocyte count (cells/mm3), viral load (> 40 copy/ml), and ART regimens were recorded. FMS diagnosis was based on 2016 revision of diagnostic criteria. All patients completed the following questionnaires: Fibromyalgia Impact Questionnaire (FIQ), Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and SF-36 scale. RESULTS FMS was found in 20% of the HIV infected patients (n = 45). The mean duration of disease was 4.74 ± 4.42 years; it was significantly longer in patients with FMS (p = 0.007). The median CD4 T-lymphocyte count was found to be 616.00 ± 303.91 cells/mm3, and it was significantly higher in patients without FMS (p = 0.06). No statistically significant difference was found between the two groups according to the drug regimens used. A statistically significant difference was found in FIQ, BDI, PSQI, FSS and all subgroups of the SF-36 scale between the patients with and without FMS (p = 0.001). CONCLUSIONS A slightly higher frequency of FMS was determined in HIV infected patients receiving ART compared to previous studies. It was shown that presence of FMS negatively affected the function, depression, fatigue, sleep, and quality of life. Detection of FMS may decrease depression, fatigue, and sleep disorders and increase the quality of life in HIV infected patients. FMS should be distinguished correctly for an accurate treatment management of HIV and for increasing ART compliance.

中文翻译：

---

合并纤维肌痛在接受抗逆转录病毒疗法的HIV感染患者中的作用：一项前瞻性横断面研究。

背景技术接受抗逆转录病毒疗法（ART）的HIV感染患者具有广泛的肌肉骨骼系统参与。关节痛和肌痛是最常见的形式。纤维肌痛综合症（FMS）是肌肉骨骼系统的慢性疼痛综合症，其特征在于弥散性疼痛，包括关节痛和肌痛。这些重叠的症状暗示了HIV和FMS之间的关系。这项研究的主要目的是确定FMS在HIV / AIDS患者中的患病率。次要目标是研究FMS对功能状态，抑郁，疲劳，睡眠方式和生活质量的影响。方法该横断面前瞻性研究共纳入225名接受ART的HIV感染患者。参与者的人口统计数据，CD4 T淋巴细胞计数（细胞/ mm3），病毒载量（> 40拷贝/ ml），并记录ART方案。FMS诊断基于2016年诊断标准的修订。所有患者均完成以下问卷：纤维肌痛影响问卷（FIQ），贝克抑郁量表（BDI），匹兹堡睡眠质量指数（PSQI），疲劳严重程度量表（FSS）和SF-36量表。结果在20％的HIV感染患者中发现了FMS（n = 45）。平均病程为4.74±4。42年；FMS患者的病程明显更长（p = 0.007）。发现CD4 T淋巴细胞的中位数为616.00±303.91细胞/ mm3，在没有FMS的患者中，其平均值显着更高（p = 0.06）。根据所使用的药物方案，两组之间没有统计学上的显着差异。FIQ，BDI，PSQI，有和没有FMS的患者之间的FSS和SF-36的所有亚组的评分（p = 0.001）。结论与先前的研究相比，接受ART的HIV感染患者确定的FMS频率略高。结果表明，FMS的存在会对功能，抑郁，疲劳，睡眠和生活质量产生负面影响。检测FMS可以减少HIV感染患者的抑郁，疲劳和睡眠障碍，并提高生活质量。FMS应该正确区分，以便对HIV进行准确的治疗管理并提高ART的依从性。抑郁，疲劳，睡眠和生活质量。检测FMS可以减少HIV感染患者的抑郁，疲劳和睡眠障碍，并提高生活质量。FMS应该正确区分，以便对HIV进行准确的治疗管理并提高ART的依从性。抑郁，疲劳，睡眠和生活质量。检测FMS可以减少HIV感染患者的抑郁，疲劳和睡眠障碍，并提高生活质量。FMS应该正确区分，以便对HIV进行准确的治疗管理并提高ART的依从性。